Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Acquire Spectral Diagnostics Cardiac Test Business for $7.7M

NEW YORK, Dec. 20 (GenomeWeb News) - Nanogen will acquire Spectral Diagnostics' rapid cardiac immunoassay test business, including the cardiac STATus, Decision Point, and i-Lynx product lines, the companies said today.


Nanogen will assume related sales, marketing, and manufacturing activities for the product lines, which it said it will combine with its own StatusFirst congestive heart failure test. The transaction, expected to close during the first quarter of 2006, is subject to approval by Spectral's shareholders.


Nanogen will pay CDN$9 million ($7.7 million) for the business, comprised of CDN$5.65 million in cash and CDN$3.35 million in Nanogen common shares, the companies said.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.